10:53

Relapsed Myeloma: Dr Manasanch

20:30

Cellular Therapy for Multiple Myeloma

02:23:54

MULTIPLE MYELOMA RELAPSED

20:16

Autologous stem cell transplant for myeloma: BTG2017

18:26

Frontline Therapy for Transplant Eligible Myeloma Patients: BTG2017

18:59

BTG2017 upfront therapy for transplant ineligible myeloma

01:14:13

BTG2017 Myeloma Session 1

55:14

BTG2017 autologous stem cell transplant for myeloma

34:57

BTG2017 frontline therapy for myeloma

16:24

BTG2017 consensus guidelines for myeloma

01:33:58

BTG2017 MULTIPLE MYELOMA NEWLY DIAGNOSED Session

02:08

BTG2017 Inauguration

04:19

BTG2017 Inauguration

01:55

BTG2017 Inauguration

08:06

BTG2017 Inauguration and Opening speech

25:18

ROLE OF CARFILZOMIB IN RELAPSED MYELOMA ROBERT ORLOWKSI

12:17

CURRENT TRIALS AND DRUGS IN PIPELINE SANJAY AGGARWAL

13:26

PROSPECTS OF IMMUNOTHERAPY IN MYELOMA JAMES CS CHIM

19:57

ELDERLY MYELOMA JAE HOON LEE

24:34

TREATMENT APPROACH FOR RELAPSED MYELOMA JEFFERY HUANG

14:46

NEWLY DIAGNOSED MYELOMA, ROBERT ORLOWKSI

14:19

RELAPSED HL: TARGETED THERAPY DAVID RITCHIE

16:22

ROLE OF PET SCAN IN CHANGING THERAPY MORTON COLEMAN

16:30

HL: AUTO VS ALLO SCT, WILLIAM HWANG

14:46

PEDIATRIC ALL: WHAT HAVE WE LEARNT IN THE PAST DECADE? ALLEN YEOH

15:52

PH +VE ALL MARCOS J DELIMA

15:27

TREATMENT ADVANCES IN ALL, DAVID RITCHIE

15:55

AN OVERVIEW OF MOLECULAR ALTERATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA WEN CHIEN CHOU

17:08

ALTERNATE DONOR TRANSPLANT IN AA SEIJI KOJIMA

21:40

UPDATE ON TRANSPLANT OPTIONS FOR AA BORJE ANDERSSON

13:56

NON TRANSPLANT OPTIONS FOR AA MOHAMAD MOTHY

15:45

HOW I TREAT CML ELIAS JABBOUR

15:29

HIGH RISK MDS/ MONOSOMY 7: TREATMENT, MOHAMAD MOHTY

08:59

UPFRONT 2ND GENERATION TKI FOR NEWLY DIAGNOSED CHRONIC PHASE CML? QIAN JIANG

13:12

WHEN TO SWITCH THERAPY IN CML? CHENG CHARLES CHUAH

13:53

CML PROGNOSTICATION AND RESPONSE/ WHEN TO DO MOLECULAR MUTATIONAL ANALYSIS? ELIAS JABBOUR

13:43

ADHERENCE/ COMPLIANCE WITH THERAPY AND MANAGEMENT OF SIDE EFFECTS RAYMOND WONG

16:54

LOW RISK MDS/ DEL 5Q: TREATMENT STEVEN KORNBLAU

17:26

DECISION TREE FOR RELAPSED REFRACTORY CML DONG WOOK KIM

12:25

ROLE OF TRANSPLANT: TIMING, SOURCE AND POST TRANSPLANT OPTIONS MARCOS DELIMA

17:27

MOLECULAR CLASSIFICATION OF MDS RAYMOND WANG

19:35

TIMING OF TRANSPLANT IN MDS, BORJE ANDERSSON

10:48

PEDIATRIC MDS: DIAGNOSIS & TREATMENT, XIAOJUAN CHEN

15:30

NEWLY DIAGNOSED AML MARCOS J DELIMA

16:00

RELAPSED AML STEVEN KORNBLAU

10:07

ALLO TRANSPLANT CAN IMPROVE CLINICAL OUTCOME FOR HIGH RISK t(8;21) AML XIAO JUN HUANG

14:47

POST TRANSPLANT THERAPIES FOR AML ELIZABETH J SHPALL

12:29

DOWN SYNDROME & LEUKEMIA SEIJI KOJIMA

12:46

ELDERLY AML ELIAS JABBOUR

11:56

IS CHEMOTHERAPY NECESSARY FOR APL THERAPY? JIONG HU

13:24

PEDIATRIC AML: DIAGNOSIS & TREATMENT DER CHERNG LIANG

15:26

CLASSSIFICATION & RISK STRATIFICATION OF AML HWEI FANG TIEN

08:34

APHCON WEB DESCRIPTION

05:50

1530-1645 Simultaneous Workshop IV

06:18

1400-1515 Simultaneous Workshop III

30:04

Aggressive Non Hodgkin's Lymphoma: Michael Wang

17:21

BTG2013 Best Abstract Award

07:45

1530-1645 Simultaneous Workshop II

06:11

1400-1515 Simultaneous Workshop I

30:51

Hodgkin's Lymphoma: Role of Transplant